Timothy Fong, Ph.D.

Timothy Fong, our Vice President of Cellular Technologies, joined Cellerant in February 2014 bringing more than 20 years of drug development experience and has led research and development groups in cell and gene therapies, bio-active peptides and recombinant proteins from discovery research to early human clinical trials in oncology and autoimmune and inflammatory diseases. Dr. Fong most recently served as Vice President of Technology & Product Development at Progenitor Cell Therapy, a wholly-owned subsidiary of Neostem. Previously, he was Director of Cell Therapy Research at Becton, Dickinson & Company, where he was responsible for the development of antibody reagents for cGMP cell isolation and Becton Dickinson's cell therapy initiative to develop a T - regulatory cell product for treatment of graft-versus-host disease (GVHD) and autoimmune diseases. Prior to joining Becton Dickinson, Dr. Fong was at Cellerant and is the original co-inventor of the Company's myeloid progenitor cell therapy program. Dr. Fong also held leadership positions at Sangstat Medical Corporation (acquired by Genzyme), Aventis Gencell and Chiron (Novartis). Dr. Fong conducted his post-doctoral training at The Salk Institute. Dr. Fong received his Ph.D. in immunology from UCLA School of Medicine, and an MBA from Saint Mary's College.


Copyright ©2006-2016 Cellerant Therapeutics, Inc.